Abstract

Adalimumab-adbm (Cyltezo) has been approved as an interchangeable biosimilar product to adalimumab (Humira). This means it can be substituted at the pharmacy for Humira without being specified in the prescription.Nurses should inform patients who have been receiving Humira that they may receive Cyltezo instead, and that this is not a pharmacy error.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call